Get the Stockscreener App
11.10
3.54%
0.38
After Hours:
11.15
0.05
+0.45%
Q 32 Bio Inc stock is traded at $11.10, with a volume of 1.82M.
It is up +3.54% in the last 24 hours and down -27.97% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
See More
Previous Close:
$10.72
Open:
$10.82
24h Volume:
1.82M
Relative Volume:
1.63
Market Cap:
$330.44M
Revenue:
$53.74M
Net Income/Loss:
$33.24M
P/E Ratio:
4.1679
EPS:
2.6632
Net Cash Flow:
$-27.40M
1W Performance:
-7.42%
1M Performance:
-27.97%
6M Performance:
+60.64%
1Y Performance:
+490.43%
1-Day Range:
$10.45
$11.27
1-Week Range:
$10.45
$12.00
52-Week Range:
$1.69
$23.57
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
11.10 | 330.44M | 53.74M | 33.24M | -27.40M | 2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | H.C. Wainwright | Buy |
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
QTTB: Q32 Bio Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround - Yahoo Finance
Q32 Bio Inc. (QTTB) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Q32 Bio to present at three major healthcare investor conferences in September 2026 - pluang.com
Q32 Bio to Participate in Upcoming September Investor Conferences - TradingView
Q32 Bio (NASDAQ: FIXX) CFO’s 3,972-share tax sale detailed - Stock Titan
Q32 Bio CFO Lee Kalowski Executes Automatic RSU Tax Withholding Share Sale - Kalkine Media
Q32 Bio CEO Jodie Morrison sells $163,033 in company stock - Investing.com
Q32 Bio CEO Jodie Morrison sells $163,033 in company stock By Investing.com - Investing.com UK
Q32 Bio (FIXX) CEO’s automatic tax sale leaves 343,259 shares - Stock Titan
Q32 Bio: A Deep Dive (NASDAQ:QTTB) - Seeking Alpha
Q32 Bio CEO Jodie Pope Morrison Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade - qz.com
Q32 Bio: The Efficacy Is Modest, The Valuation Is Not (NASDAQ:QTTB) - Seeking Alpha
Q32 Bio Sees Unusually Large Options Volume (NASDAQ:QTTB) - MarketBeat
Q32 (QTTB) Earnings Snapshot: The Bottom-Line Figure Outpaces Its Comparison for the Current Session; Price Move - vinanet.vn
Q32 Bio Company Profile & Introduction - Moomoo
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? - Yahoo Finance
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Q32 Bio (NASDAQ:QTTB) stock in focus after mid-stage trial data - Kalkine Media
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Renaissance Technologies LLC Acquires 107,315 Shares of Q32 Bio Inc. $QTTB - MarketBeat
Q32 Bio (QTTB) Advances 2.34% as Shares Hold Above Key SupportMean Reversion Trade - vinanet.vn
Q32 Bio (QTTB) Holds Near $15.37 as Shares Consolidate Between Key Support and ResistanceGamma Squeeze - vinanet.vn
Q32 Bio Inc (NASDAQ: QTTB) Stock Price, News & Analysis - Kalkine
Q32 Bio Inc (QTTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Forecasts Q32 Bio's Q3 Earnings (NASDAQ:QTTB) - MarketBeat
Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Q32 Bio Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Q32 Bio tops estimates as alopecia drug advances toward late-stage trials (QTTB:NASDAQ) - Seeking Alpha
Q32 Bio Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Q32 Bio Inc. posts second quarter 2026 results and updates corporate outlook - Traders Union
Q32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingView
Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary - TradingView
Q32 Bio (Nasdaq: QTTB) adds $187.6M follow-on cash for AA drug - Stock Titan
Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise - Stock Titan
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Q32 Bio Announces Q2 2026 Financial Results Highlighting Clinical-Stage Progress and Capital Needs - Kalkine Media
Q32 Bio Inc. Revenue Breakdown – NASDAQ:QTTB - TradingView
Q32 Bio Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Q32 Bio Inc. (QTTB) investors disclose 5.49% stake in Schedule 13G/A - stocktitan.net
Q32 Bio Inc. SEC Filing (Jul 29, 2026) - stocktitan.net
H.C. Wainwright raises Q32 Bio stock price target to $36 on alopecia drug outlook - Investing.com
Q32 Bio Inc (QTTB) Balance Sheet - TradingKey
Q32 Bio Inc (QTTB) Income Statement - TradingKey
Q32 Bio Inc (QTTB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Q32 Bio Inc (QTTB) Cash Flow - TradingKey
QTTB|Q32 Bio Inc|Price:15.060|Chg%:-0.150 - TradingKey
QTTB|Q32 Bio Inc|Price:15.140|Chg%:-0.010 - TradingKey
Q32 Bio Inc (QTTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Q 32 Bio Inc Stock (QTTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):